ArticleScientific reports2021
Clinical characterization and outcomes of 85 patients with neurosarcoidosis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Neurosarcoidosis in children: A systematic review and summary of cases, imaging and management.Journal of neuroimmunology · 2022Pooled it
- Systemic Sarcoidosis With Neurosarcoidosis and Obstructive Hydrocephalus: A Radiologic-Pathologic Case Report.Journal of medical cases · 2026Article
- Estimated prevalence and distribution of causes of immune-mediated hypertrophic pachymeningitis in São Paulo, Brazil.Clinical rheumatology · 2026Article
- An update on hypophysitis.Nature reviews. Endocrinology · 2026Review
- Isolated cerebellopontine angle neurosarcoidosis mimicking meningioma: a diagnostic pitfall. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Neurosarcoidosis: a review from diagnosis and future perspectives.EClinicalMedicine · 2025Review
- Panhypopituitarism in Neurosarcoidosis: Pituitary-Hypothalamic Involvement Successfully Managed With Rituximab.JCEM case reports · 2025Article
- Clinical and Laboratory Characteristics of Patients with Neurosarcoidosis.Noro psikiyatri arsivi · 2025Article
- Central Nervous System Sarcoidosis: A National-Based registry study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Granuloma, vasculitis, and demyelination in sarcoid neuropathy.European journal of neurology · 2024Article
- Isolated neurosarcoidosis with a primary lesion in the cauda equina.BMJ case reports · 2023Article
- Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.Current oncology (Toronto, Ont.) · 2023Review
- A comprehensive diagnostic approach in suspected neurosarcoidosis.Scientific reports · 2023Article
- Insights into neurosarcoidosis: an imaging perspective.Polish journal of radiology · 2023Review
- Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction.Frontiers in neurology · 2023Article
- High-resolution ultrasound of peripheral neuropathies in rheumatological patients: An overview of clinical applications and imaging findings.Frontiers in medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To analyze the frequency and clinical phenotype of neurosarcoidosis (NS) in one of the largest nationwide cohorts of patients with sarcoidosis reported from southern Europe. NS was evaluated according to the Diagnostic Criteria for Central Nervous System and Peripheral Nervous System Sarcoidosis recently proposed by Stern et al. Pathologic confirmation of granulomatous disease was used to subclassify NS into definite (confirmation in neurological tissue), probable (confirmation in extraneurological tissue) and possible (no histopathological confirmation of the disease). Of the 1532 patients included in the cohort, 85 (5.5%) fulfilled the Stern criteria for NS (49 women, mean age at diagnosis of NS of 47.6 years, 91% White). These patients developed 103 neurological conditions involving the brain (38%), cranial nerves (36%), the meninges (3%), the spinal cord (10%) and the peripheral nerves (14%); no patient had concomitant central and peripheral nerve involvements. In 59 (69%) patients, neurological involvement preceded or was present at the time of diagnosis of the disease. According to the classification proposed by Stern et al., 11 (13%) were classified as a definite NS, 61 (72%) as a probable NS and the remaining 13 (15%) as a possible NS. In comparison with the systemic phenotype of patients without NS, patients with CNS involvement presented a lower frequency of thoracic involvement (82% vs 93%, q = 0.018), a higher frequency of ocular (27% vs 10%, q < 0.001) and salivary gland (15% vs 4%, q = 0.002) WASOG involvements. In contrast, patients with PNS involvement showed a higher frequency of liver involvement (36% vs 12%, p = 0.02) in comparison with patients without NS. Neurosarcoidosis was identified in 5.5% of patients. CNS involvement prevails significantly over PNS involvement, and both conditions do not overlap in any patient. The systemic phenotype associated to each involvement was clearly differentiated, and can be helpful not only in the early identification of neurological involvement, but also in the systemic evaluation of patients diagnosed with neurosarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.